PDAC-PATHWAYS: A Digital Informational and Supportive Care App for Patients Initiating Neoadjuvant Therapy for Pancreatic Ductal Adenocarcinoma

There are two parts of this study. Study Part 1 is an open pilot study to refine PDAC-PATHWAYS prior to larger-scale testing in a randomized controlled trial (RCT) setting. Study Part 1 is purely descriptive, as the investigators will use the data to refine PDAC-PATHWAYS before proceeding to Study Part 2.

Study Part 2 is a pilot RCT to assess the feasibility and acceptability of conducting a randomized trial of PDAC-PATHWAYS versus usual care. Participants will complete a baseline survey and then be randomized to PDAC-PATHWAYS versus usual care. This record reflects the clinical trial component (Study Part 2), as feasibility and acceptability outcomes will be collected for this phase only.

• PDAC-PATHWAYS (Behavioral): A digital app for patients initiating neoadjuvant therapy for PDAC
• Usual Care (Other): Routine treatment

Primary outcomes

• Feasibility: Enrollment rate [10 weeks]: ≥50% enrollment among consecutive eligible patients
• Feasibility: intervention completion rate [10 weeks]: ≥50% completion of at least four app modules among those assigned to the intervention

Secondary outcomes

• Acceptability [10 weeks]: ≥70% of patients in the intervention arm reporting Client Satisfaction Questionnaire-8 scores at or above the midpoint score of 20 on a scale from 8-32 (higher scores indicate higher satisfaction)

Sex: All, ages: 18 Years to any

Inclusion Criteria:

* Age≥18 years
* Within 8 weeks of a documented decision to pursue neoadjuvant therapy for newly diagnosed, non-metastatic PDAC
* Able to comprehend and speak English

Exclusion Criteria:

* Comorbid health condition that would interfere with study participation, as identified by the cancer care team